SEC Form 4 · accession 0001213900-26-075538
BridgeBio Oncology Therapeutics, Inc. · BBOT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bihua Chen
Director · 10% Owner
Period of report
Jul 1, 2026
Accepted (ET)
Jul 6, 2026 · 4:34 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001869105
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF5 | Jul 1, 2026 | J | 4,528,186 | $0.00 | D | 0 | I | Via Helix Holdings II LLC |
| Common StockF6 | Jul 1, 2026 | J | 2,692,459 | $0.00 | A | 4,879,995 | I | Via Fund III |
| Common StockF6 | Jul 1, 2026 | J | 1,704,862 | $0.00 | A | 5,010,332 | I | Via Fund V |
| Common StockF6 | Jul 1, 2026 | J | 130,865 | $0.00 | A | 6,083,221 | I | Via Master Fund |
| Common StockF6 | holding | — | — | — | 1,905,046 | I | Via Fund IV |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a pro rata distribution to the members of Helix Holdings II LLC (the "Sponsor") for no consideration.
- F2Cormorant Private Healthcare Fund III, LP ("Fund III"), which is an investment vehicle managed by Cormorant Asset Management, LP ("CAM"), is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration.
- F3Cormorant Private Healthcare Fund V, LP ("Fund V"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration.
- F4Cormorant Global Healthcare Master Fund, LP ("Master Fund"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration.
- F5Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly.
- F6CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP ("Fund IV"), Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly.
Remarks
Ms. Chen serves on the Board of Directors of the Issuer. Sponsor and the Cormorant Funds may be deemed to be directors by deputization as a result of the service of Ms. Chen.